INFANT'S ADVIL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for INFANT'S ADVIL (INFANT'S ADVIL).
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
| Metabolism | Primarily hepatic via CYP2C9 and CYP2C8; also undergoes glucuronidation. |
| Excretion | Renal excretion of metabolites (primarily glucuronide and sulfate conjugates of ibuprofen) accounts for approximately 90% of elimination, with less than 10% excreted unchanged in urine. Biliary/fecal excretion is minimal (<5%). |
| Half-life | Terminal elimination half-life is approximately 1.5 to 2 hours in infants and children, which is shorter than in adults (2-4 hours). This shorter half-life reflects higher clearance in pediatric populations and has clinical implications for dosing frequency (typically every 6-8 hours). |
| Protein binding | Approximately 99% bound to plasma proteins, primarily albumin. This high binding can affect distribution and elimination, especially in conditions with hypoalbuminemia. |
| Volume of Distribution | Approximately 0.1-0.2 L/kg in infants and children, indicating limited extravascular distribution. This low Vd correlates with high plasma protein binding and minimal tissue penetration. |
| Bioavailability | Oral suspension: >80% bioavailability (first-pass metabolism is minimal but variable). The infant formulation has similar bioavailability to adult tablets, though absorption may be slightly more rapid due to liquid form. |
| Onset of Action | Oral administration (suspension): Antipyretic effect begins within 15-30 minutes, with peak effect at 1-2 hours. Analgesic effect onset is similar. |
| Duration of Action | Antipyretic and analgesic effects last approximately 6-8 hours. Duration may be slightly shorter in infants due to faster clearance. Clinical note: The suspension formulation is designed for 6-8 hour dosing intervals. |
| Molecular Weight | 206.28 |
200-400 mg orally every 4-6 hours as needed; maximum daily dose 1200 mg.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | eGFR 30-60 mL/min: reduce dose by 25-50%; eGFR <30 mL/min: avoid use. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use. |
| Pediatric use | 5-10 mg/kg/dose orally every 6-8 hours as needed; maximum single dose 400 mg; maximum daily dose 40 mg/kg or 1200 mg (whichever is less). |
| Geriatric use | Start at lowest effective dose (e.g., 200 mg) and limit daily dose to 800 mg due to increased risk of GI bleeding and renal impairment. |
| 1st trimester | Avoid use during first trimester: associated with increased risk of miscarriage and congenital malformations (e.g., cardiac defects, gastroschisis). NSAIDs should be avoided unless absolutely necessary. |
| 2nd trimester | Use with caution: may be used if benefit outweighs risk, but exposure should be at the lowest effective dose and shortest duration due to risks of oligohydramnios and premature ductus arteriosus constriction. |
| 3rd trimester | Contraindicated after 30 weeks gestation: NSAIDs can cause premature closure of the ductus arteriosus, oligohydramnios, and neonatal renal impairment. Avoid use. |
Clinical note
Comprehensive clinical and safety monograph for INFANT'S ADVIL (INFANT'S ADVIL).
| Placental transfer | Ibuprofen crosses the placenta; fetal concentrations are approximately 30% of maternal serum levels. Evidence of transfer in both early and late pregnancy. |
| Breastfeeding | Ibuprofen is excreted into breast milk in very low concentrations (0.0006%–0.6% of maternal dose). It is considered compatible with breastfeeding; however, monitor infant for potential adverse effects such as rash, diarrhea, or irritability. Prefer short-term use at lowest effective dose. |
■ FDA Black Box Warning
NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
| Serious Effects |
History of hypersensitivity to ibuprofen or any NSAIDActive peptic ulcer disease or gastrointestinal bleedingSevere hepatic impairmentSevere renal impairment (CrCl <30 mL/min)Perioperative pain management in coronary artery bypass graft (CABG) surgeryThird trimester of pregnancy (after 30 weeks gestation)
| Precautions | Cardiovascular thrombotic events, gastrointestinal bleeding, ulceration, and perforation; renal toxicity; hypertension; anaphylactoid reactions; serious skin reactions; hematologic toxicity; use with caution in patients with asthma; avoid use in late pregnancy. |
| Food/Dietary | No significant food interactions. Administer with food or milk to minimize gastrointestinal irritation. |
Loading safety data…
| Lactation Rating | L1 (Safest) – Compatible with breastfeeding based on limited human data. |
| Teratogenic Risk | First trimester: NSAIDs may increase risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Second trimester: Generally considered lower risk but use is not recommended unless clearly needed. Third trimester: Avoid due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. |
| Fetal Monitoring | Ultrasound for amniotic fluid index if prolonged use; fetal echocardiography if third trimester exposure; monitor maternal renal function, blood pressure, and signs of bleeding. |
| Fertility Effects | NSAIDs may impair female fertility via inhibition of prostaglandin synthesis, affecting ovulation and implantation. Reversible upon discontinuation. Male fertility effects are not well established. |
| Clinical Pearls | Ibuprofen is contraindicated in infants with suspected or confirmed varicella due to increased risk of invasive group A streptococcal infection. Use weight-based dosing (5-10 mg/kg/dose) rather than age-based to ensure therapeutic efficacy and safety. Avoid use in infants with dehydration, as it may precipitate acute kidney injury. |
| Patient Advice | Give with food or milk to reduce stomach upset. · Use weight-based dosing with the provided syringe; do not exceed 4 doses in 24 hours. · Do not use if infant is dehydrated (e.g., vomiting, diarrhea, poor intake) or has chickenpox. · Do not give with other NSAIDs or acetaminophen unless directed by a doctor. · Stop use and call doctor if fever lasts >3 days, pain lasts >10 days, or new symptoms occur. |